Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.

Ju RJ, Li XT, Shi JF, Li XY, Sun MG, Zeng F, Zhou J, Liu L, Zhang CX, Zhao WY, Lu WL.

Biomaterials. 2014 Aug;35(26):7610-21. doi: 10.1016/j.biomaterials.2014.05.040. Epub 2014 Jun 7.

PMID:
24912818
2.

Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.

Sun MG, Shi JF, Li XY, Zhao Y, Ju RJ, Mu LM, Yan Y, Li XT, Zeng F, Lu WL.

J Biomed Nanotechnol. 2015 Aug;11(8):1339-53.

PMID:
26295137
3.

Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.

Ju RJ, Zeng F, Liu L, Mu LM, Xie HJ, Zhao Y, Yan Y, Wu JS, Hu YJ, Lu WL.

Int J Nanomedicine. 2016 Mar 21;11:1131-46. doi: 10.2147/IJN.S94467. eCollection 2016.

4.

A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer.

Shi JF, Sun MG, Li XY, Zhao Y, Ju RJ, Mu LM, Yan Y, Li XT, Zeng F, Lu WL.

J Biomed Nanotechnol. 2015 Sep;11(9):1568-82.

PMID:
26485927
5.

Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma.

Li XY, Zhao Y, Sun MG, Shi JF, Ju RJ, Zhang CX, Li XT, Zhao WY, Mu LM, Zeng F, Lou JN, Lu WL.

Biomaterials. 2014 Jul;35(21):5591-604. doi: 10.1016/j.biomaterials.2014.03.049. Epub 2014 Apr 13.

PMID:
24726749
6.

Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer.

Zeng F, Ju RJ, Liu L, Xie HJ, Mu LM, Zhao Y, Yan Y, Hu YJ, Wu JS, Lu WL.

Oncotarget. 2015 Nov 3;6(34):36625-42. doi: 10.18632/oncotarget.5382.

7.

Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.

Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P.

Breast Cancer Res. 2005;7(4):R422-35. Epub 2005 Apr 4.

8.

Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.

Guo Z, He B, Yuan L, Dai W, Zhang H, Wang X, Wang J, Zhang X, Zhang Q.

Int J Pharm. 2015 Sep 30;493(1-2):380-9. doi: 10.1016/j.ijpharm.2015.05.051. Epub 2015 May 21.

PMID:
26004003
9.

Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.

Jiang L, Li L, He X, Yi Q, He B, Cao J, Pan W, Gu Z.

Biomaterials. 2015 Jun;52:126-39. doi: 10.1016/j.biomaterials.2015.02.004. Epub 2015 Feb 24.

PMID:
25818419
10.

Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.

Li N, Zhang CX, Wang XX, Zhang L, Ma X, Zhou J, Ju RJ, Li XY, Zhao WY, Lu WL.

Biomaterials. 2013 Apr;34(13):3366-80. doi: 10.1016/j.biomaterials.2013.01.055. Epub 2013 Feb 11.

PMID:
23410681
11.

The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells.

Wang XX, Li YB, Yao HJ, Ju RJ, Zhang Y, Li RJ, Yu Y, Zhang L, Lu WL.

Biomaterials. 2011 Aug;32(24):5673-87. doi: 10.1016/j.biomaterials.2011.04.029. Epub 2011 May 7.

PMID:
21550109
12.

Multifunctional Tandem Peptide Modified Paclitaxel-Loaded Liposomes for the Treatment of Vasculogenic Mimicry and Cancer Stem Cells in Malignant Glioma.

Liu Y, Mei L, Yu Q, Xu C, Qiu Y, Yang Y, Shi K, Zhang Q, Gao H, Zhang Z, He Q.

ACS Appl Mater Interfaces. 2015 Aug 5;7(30):16792-801. doi: 10.1021/acsami.5b04596. Epub 2015 Jul 22.

PMID:
26173814
13.

Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.

Yu Y, Wang ZH, Zhang L, Yao HJ, Zhang Y, Li RJ, Ju RJ, Wang XX, Zhou J, Li N, Lu WL.

Biomaterials. 2012 Feb;33(6):1808-20. doi: 10.1016/j.biomaterials.2011.10.085. Epub 2011 Dec 1.

PMID:
22136714
14.

Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice.

Zhang S, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K.

Breast Cancer Res Treat. 2004 Sep;87(2):111-21.

PMID:
15377836
15.

LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics.

Wang Z, Yu Y, Ma J, Zhang H, Zhang H, Wang X, Wang J, Zhang X, Zhang Q.

Mol Pharm. 2012 Sep 4;9(9):2646-57. doi: 10.1021/mp3002107. Epub 2012 Aug 13.

PMID:
22853186
16.

A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.

Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR, Pockaj BA, Mukherjee P.

Breast Cancer Res. 2006;8(6):R69.

17.

A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment.

Zhang CX, Zhao WY, Liu L, Ju RJ, Mu LM, Zhao Y, Zeng F, Xie HJ, Yan Y, Lu WL.

Oncotarget. 2015 Oct 20;6(32):32681-700. doi: 10.18632/oncotarget.5354.

18.

Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.

Gao W, Xiang B, Meng TT, Liu F, Qi XR.

Biomaterials. 2013 May;34(16):4137-49. doi: 10.1016/j.biomaterials.2013.02.014. Epub 2013 Mar 1.

PMID:
23453200
19.

Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.

Shahin M, Soudy R, Aliabadi HM, Kneteman N, Kaur K, Lavasanifar A.

Biomaterials. 2013 May;34(16):4089-97. doi: 10.1016/j.biomaterials.2013.02.019. Epub 2013 Mar 5.

PMID:
23465829
20.

Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.

Sun J, Jiang L, Lin Y, Gerhard EM, Jiang X, Li L, Yang J, Gu Z.

Int J Nanomedicine. 2017 Feb 27;12:1517-1537. doi: 10.2147/IJN.S122859. eCollection 2017.

Supplemental Content

Support Center